Alprazolam is a high potency triazolobenzodiazepine that is approved in Australia for the treatment of anxiety and panic disorders, however, is associated with a disproportionate amount of harm compared to other benzodiazepines. Amid growing concerns of misuse and harms, increased restrictions were introduced on 1 February 2014 in Australia, whereby alprazolam was up scheduled from Schedule 4 to Schedule 8. It is the purpose of this presentation to examine the impact of this rescheduling among a sample of people who inject drugs (PWID), from 2011-2018.